What is the Aspira Pathlab & Diagnostics Ltd share price today?

The share price of BSE:ASPIRA-XT on 07 Sep 2026 (as of 11:00:46 IST) is ₹97.21.

What is the BSE:ASPIRA-XT 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the BSE:ASPIRA-XT 52 week high low range shows a high of ₹135.88 and a low of ₹49.00.

What is the Aspira Pathlab & Diagnostics Ltd market cap?

As on 07 Sep 2026, Aspira Pathlab & Diagnostics Ltd market cap is ₹99.84 Cr.

What is the shareholding pattern of Aspira Pathlab & Diagnostics Ltd Stock?

The shareholding pattern of Aspira Pathlab & Diagnostics Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 46.58% Foreign Institutional Investors (FII): 0% Domestic Institutional Investors (DII): 0% Mutual Funds: 0% Retail & Others: 53.42% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Aspira Pathlab & Diagnostics Ltd?

The Price-to-Earnings (PE) ratio of Aspira Pathlab & Diagnostics Ltd is 41.62, and the Price-to-Book (PB) ratio is 7.21, as on 07 Sep 2026.

Aspira Pathlab & Diagnostics Share Price

129.50-3.61 (-2.71%)

+103.30% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-2.71%

1 Week

+12.61%

1 Month

+49.71%

3 Month

-1.33%

6 Month

+136.53%

YTD

+95.68%

1 Year

+103.30%

5 Year

+71.86%

10 Year

Max

+238.12%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

129.50

120.75

86.50

81.35

49.00

High

138.99

About

Aspira Pathlab & Diagnostics Limited is solely engaged in the business of running laboratories for carrying out Pathological investigations in various branches of Bio-chemistry, Hematology, Histopathology, Microbiology, Immuno-chemistry, Immunology, Virology, Read more

Hospital & Healthcare Services

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

APOLLOHOSP-ANSE

MAXHEALTH-ANSE

FORTIS-ANSE

ASTERDM-ANSE

MEDANTA-ANSE

NH-ANSE

KIMS-ANSE

LALPATHLAB-ANSE

VIJAYA-ANSE

AGARWALEYE-ANSE

ASPIRA-XNSE

LTP

1W Low

1W High

Market cap (₹)

8900+129.75 (1.48%)

8816.40

9069

1,30,273Cr

1047.5-7.5 (-0.71%)

1029.20

1072

1,02,446Cr

878.75+3.75 (0.43%)

878.75

908.20

67,267Cr

770.55+14.7 (1.94%)

739.70

779.80

66,295Cr

1502.25-4.5 (-0.30%)

1400.90

1525.65

40,209Cr

1879.55-50.2 (-2.60%)

1871.50

1931.45

39,270Cr

802-9 (-1.11%)

786.45

818.85

33,529Cr

1958.8+62.95 (3.32%)

1888.90

1975

32,271Cr

1531-26.5 (-1.70%)

1507

1592

16,149Cr

503+3.2 (0.64%)

484.85

506

15,713Cr

129.5+14.5 (12.61%)

120.75

138.99

137Cr

Aspira Pathlab & Diagnostics Share Price

129.50-3.61 (-2.71%)

+103.30% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years-

Last year67%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year176%

Stock Price CAGR

10 years-

5 years12%

3 years56%

1 year109%

Return on Equity

10 years-4%

5 years-4%

3 years-4%

Last year18%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	-	67%
-	-	-	176%
-	12%	56%	109%
-4%	-4%	-4%	18%

Peer Comparison

Symbol

APOLLOHOSP-A

MAXHEALTH-A

FORTIS-A

ASTERDM-A

MEDANTA-A

NH-A

KIMS-A

LALPATHLAB-A

VIJAYA-A

AGARWALEYE-A

ASPIRA-X

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
8,900	₹130273 Cr	62.35	40.39	207.67	₹1942 Cr
1,047.5	₹102446 Cr	70.32	3.31	19.84	₹1442 Cr
878.75	₹67267 Cr	64.19	3.53	20.1	₹1042 Cr
770.55	₹66295 Cr	208.03	0.31	6.76	₹388 Cr
1,502.25	₹40209 Cr	72.3	5.91	29.85	₹556 Cr
1,879.55	₹39270 Cr	48.12	10.14	65.36	₹806 Cr
802	₹33529 Cr	164.12	1.04	12.74	₹241 Cr
1,958.8	₹32271 Cr	59.55	10.11	42.51	₹505 Cr
1,531	₹16149 Cr	86.13	5.16	27.53	₹173 Cr
503	₹15713 Cr	105.91	1.43	13.88	₹133 Cr
129.5	₹137 Cr	57.11	0.41	3.77	₹2 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Unsecured Loans

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Provisions

Total Current Liabilities

Total Liabilities

Contingent Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2025	Mar 2024
—	—
₹10 Cr	₹10 Cr
₹2 Cr	-₹15 L
₹2 Cr	-₹15 L
₹12 Cr	₹10 Cr
₹1 Cr	₹1 Cr
₹1 Cr	₹1 Cr
₹55 L	₹41 L
₹3 Cr	₹2 Cr
—	—
₹74 L	₹73 L
₹2 Cr	₹1 Cr
₹5 L	₹3 L
₹2 Cr	₹2 Cr
₹17 Cr	₹15 Cr
₹1 Cr	₹1 Cr
₹1 Cr	₹1 Cr
—	—
₹18 Cr	₹17 Cr
₹12 Cr	₹10 Cr
₹7 Cr	₹7 Cr
₹8 L	₹0
₹8 L	₹0
₹4 Cr	₹4 Cr
₹2 Cr	₹0
₹12 Cr	₹10 Cr
—	—
₹51 L	₹45 L
₹2 Cr	₹2 Cr
₹2 Cr	₹1 Cr
₹8 L	₹6 L
₹27 L	₹22 L
₹5 Cr	₹4 Cr
₹3 Cr	₹2 Cr
₹17 Cr	₹15 Cr
₹12	₹10
₹12	₹10

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2025	Mar 2024
₹2 Cr	-₹3 Cr
₹2 Cr	₹2 Cr
-₹2 Cr	₹2 Cr
₹2 Cr	₹1 Cr
₹2 Cr	₹1 Cr
₹12 L	₹14 L
-₹99 L	-₹95 L
₹95 L	₹24 L
₹80 L	₹57 L
₹2 Cr	₹80 L

Fundamental Ratios

Consolidated

Standalone

Aspira Pathlab & Diagnostics Share Price

129.50-3.61 (-2.71%)

+103.30% past 1 Year

Shareholding summary

Promoters

46.58%

FII

DII

Others

53.42%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
46.58%	18.39%	18.39%	18.39%	18.39%	18.39%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
53.42%	81.61%	81.61%	81.61%	81.61%	81.61%

Bulk & block deals

Name

Vinod Chandulal Mav

Investeria Financial Services Private Limited

Divya Kanda

Devji Deyat Nanda

Adequate Real Trade Llp

Rajesh Premji Bhanushali

Socradamus Capital Private Limited .

Glorious Holdings Pvt Ltd

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
21 Jul 2026	Purchase	47.70 L	₹88.50	53.90 K	Bulk	0.523657	BSE
21 Jul 2026	Sell	91.98 L	₹88.67	1.04 L	Bulk	1.007792	BSE
17 Jul 2026	Sell	85 L	₹85	1 L	Bulk	0.971534	BSE
09 Oct 2025	Purchase	31.05 L	₹59.56	52.13 K	Bulk	0.506461	BSE
09 Oct 2025	Sell	9.12 L	₹61.97	14.72 K	Bulk	0.14302	BSE
06 Oct 2025	Sell	67.73 L	₹75.26	90 K	Bulk	0.874381	BSE
25 Aug 2025	Purchase	42.47 L	₹58.99	72 K	Bulk	0.699505	BSE
02 Jul 2024	Purchase	19.46 L	₹28.34	68.68 K	Bulk	0.667269	BSE
02 Jul 2024	Sell	36.06 L	₹28.85	1.25 L	Bulk	1.214418	BSE
28 Jun 2024	Sell	22.50 L	₹30	75 K	Bulk	0.728651	BSE

Insider trading & SAST

Client name

Jay Arvind Bhanushali

Nikunj Mange & Pacs

Deepali Arvind Bhanushali & Pacs

Raj Arvind Bhanushali & Pacs

Shraddha Bhanushali & Pacs

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
23 Sep 2026	Promoter	Acquisition	—	7.24	0	—	332	25 Aug 2026	Market	7,44,797	SAST	29(2)	—
17 Sep 2026	Promoter	Acquisition	0.013475	7.27	1.34 L	₹96.91	1.39 K	11 Sep 2026 - 16 Sep 2026	Market Purchase	7,47,838	Insider Trading	—	Equity
12 Sep 2026	Promoter	Acquisition	0.000719	7.25	7 K	₹94.55	74	10 Sep 2026	Market Purchase	7,46,451	Insider Trading	—	Equity
05 Sep 2026	Promoter	Acquisition	0.009298	7.25	87.88 K	₹91.83	957	31 Aug 2026 - 01 Sep 2026	Market Purchase	7,45,754	Insider Trading	—	Equity
05 Sep 2026	Promoter	Acquisition	0.006053	7.25	56.28 K	₹90.33	623	02 Sep 2026 - 03 Sep 2026	Market Purchase	7,46,377	Insider Trading	—	Equity
28 Aug 2026	Promoter	Acquisition	0.003225	7.24	28.72 K	₹86.50	332	25 Aug 2026	Market Purchase	7,44,797	Insider Trading	—	Equity
17 Jun 2026	Promoter	Acquisition	22.18	46	0	—	22.83 L	08 Jun 2026	Open Offer	47,34,618	SAST	29(2)	—
17 Jun 2026	Promoter	Acquisition	22.18	46	0	—	22.83 L	08 Jun 2026	Open Offer	47,34,617	SAST	29(2)	—
17 Jun 2026	Promoter	Acquisition	22.18	46	0	—	22.83 L	08 Jun 2026	Open Offer	47,34,618	SAST	29(2)	—
17 Jun 2026	Promoter	Acquisition	22.18	46	0	—	22.83 L	08 Jun 2025	Open Offer	47,34,618	SAST	29(2)	—

Aspira Pathlab & Diagnostics Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Aspira Pathlab & Diagnostics Share Price

Aspira Pathlab & Diagnostics Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Aspira Pathlab & Diagnostics Share Price

Aspira Pathlab & Diagnostics Share Price

Oscillators

Moving averages

Aspira Pathlab & Diagnostics Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Aspira Pathlab & Diagnostics Share Price

Corporate Actions

Company details

Aspira Pathlab & Diagnostics Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Aspira Pathlab & Diagnostics Share Price

News

Aspira Pathlab & Diagnostics informs about disclosure

Aspira Pathlab & Diagnostics informs about updates

Aspira Pathlab & Diagnostics informs about disclosure

Aspira Pathlab&Diagn reports Profit after tax of Rs -68.90 Lakhs, in the March 2026 quarter

Aspira Pathlab & Diagnostics informs about confirmation certificate

Aspira Pathlab&Diagn reports Profit after tax of Rs -1.56 Crores, in the December 2025 quarter

Aspira Pathlab&Diagn reports Profit after tax of 1.83 Crores, in the September 2025 quarter

Aspira Pathlab&Diagn reports Profit after tax of 47.00 Lakhs, in the June 2025 quarter

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab&Diagn reports Profit after tax of 72.30 Lakhs, in the March 2025 quarter

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab & Diagnostics informs about contact details of RTA

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab&Diagn reports Profit after tax of 37.60 Lakhs, in the December 2024 quarter

Aspira Pathlab&Diagn - Quaterly Results

Aspira Pathlab&Diagn reports Profit after tax of 98.90 Lakhs, in the September 2024 quarter

Aspira Pathlab & Diagnostics informs about newspaper publication

Aspira Pathlab & Diagnostics informs about book closure

Aspira Pathlab & Diagnostics Ltd Share Price Today

Aspira Pathlab & Diagnostics Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator